Principal Financial Group
SPRY icon

Principal Financial Group’s ARS Pharmaceuticals SPRY Stock Holding History

Principal Financial Group’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$238K Buy
+29,727
New +$256K ﹤0.01% 2070
2026
Q1 		– Sell
-112,766
Closed -$1.31M – 2284
2025
Q4 		$1.31M Buy
112,766
+35,882
+47% +$349K ﹤0.01% 1912
2025
Q3 		$773K Buy
76,884
+21,438
+39% +$308K ﹤0.01% 1972
2025
Q2 		$968K Buy
+55,446
New +$800K ﹤0.01% 1892
2024
Q3 		– Sell
-10,230
Closed -$87.1K – 2397
2024
Q2 		$87.1K Buy
+10,230
New +$90.8K ﹤0.01% 2233

Other funds holding SPRY

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Janney Montgomery Scott
Janney Montgomery Scott Philadelphia, Pennsylvania $51.6B AUM 27.34% 1-Year Est. Return
GAI
General American Investors New York $1.69B AUM 40.94% 1-Year Est. Return
PCM
Peregrine Capital Management Minneapolis, Minnesota $3.08B AUM 29.51% 1-Year Est. Return
PCML
Pavaki Capital Management LLC Pueblo, Colorado $287M AUM
LCS
Levin Capital Strategies New York $1.49B AUM 30.44% 1-Year Est. Return
ELI
Empire Life Investments Toronto, Ontario, Canada $1.79B AUM 38.49% 1-Year Est. Return
KPF
K2 Principal Fund Toronto, Ontario, Canada $1.36B AUM 25.57% 1-Year Est. Return

Principal Financial Group's SPRY Position: Q2 2026 in Review

Principal Financial Group opened a new position in ARS Pharmaceuticals (SPRY) in Q2 2026: 29,727 shares worth $238K. The stake represents ﹤0.01% of the portfolio and ranks #2070 among its holdings. This is a return to the name: Principal Financial Group previously reported a position in SPRY as recently as Q4 2025.

Principal Financial Group first reported a position in SPRY in Q2 2024 and has held it in 5 quarters since. The position peaked at $1.31M in Q4 2025. 68 funds tracked by Wall St. Rank hold SPRY as of Q2 2026.

  • Principal Financial Group held 29,727 shares of ARS Pharmaceuticals worth $238K as of Q2 2026.
  • ARS Pharmaceuticals was a new Principal Financial Group position in Q2 2026.
  • ARS Pharmaceuticals made up ﹤0.01% of Principal Financial Group's portfolio in Q2 2026, its #2070 holding.
  • Principal Financial Group first reported a position in ARS Pharmaceuticals in Q2 2024 and has held it in 5 quarters since.
  • Principal Financial Group's ARS Pharmaceuticals position peaked at $1.31M in Q4 2025.
  • 68 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2026.

Based on Principal Financial Group's 13F filing for Q2 2026, filed 4 Aug 2026.